针对先前在转移性激素敏感阶段接受过三联疗法的转移性去势抵抗性前列腺癌患者的治疗。
Treatments for Patients with Metastatic Castration-resistant Prostate Cancer Who Previously Received Triplet Therapy at the Metastatic Hormone-sensitive Stage.
发表日期：2024 Oct 17
作者：
Yohann Loriot, Karim Fizazi
来源：
European Urology Focus
摘要：
目前，三联疗法后前列腺癌进展的治疗证据水平较低。强烈建议对患者进行分子分析并参加临床试验。版权所有 © 2024 欧洲泌尿外科协会。由 Elsevier B.V. 出版。保留所有权利。
The level of evidence for the management of prostate cancer progressing after triplet therapy is currently low. Molecular profiling of patients and enrolment in clinical trials are strongly recommended.Copyright © 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.